Alendronate

Introduction Overview

Generic Name

alendronate

Brand Name

Fosamax, Binosto

Dosage Form

Oral tablet and oral effervescent tablet

Drug Class

Bisphosphonates

Pharmacokinetics

Absorption: Alendronate exhibits poor oral bioavailability, approximating 0.6% to 1% when fasting, with absorption markedly decreased by food and beverages other than plain water. Peak plasma concentrations occur within 1 to 2 hours post-dose. The bioavailability is significantly reduced when taken with calcium-containing products, antacids, or other oral supplements, necessitating dosing on an empty stomach with plain water and withholding food or other medications for at least 30 minutes post administration.

Distribution: After absorption, alendronate displays rapid skeletal uptake where it preferentially binds to hydroxyapatite crystals in areas of active bone remodeling. Approximately 50% to 60% of the absorbed dose localizes in bone, with the remainder excreted unchanged primarily by the renal route. Plasma protein binding is negligible. Bone distribution is heterogeneous, concentrating in areas with increased resorption, which allows targeting of areas vulnerable to pathologic bone loss.

Metabolism: Alendronate is not metabolized by the liver or other tissues; it remains structurally unchanged throughout its duration in the body. This lack of metabolic processing reduces the potential for drug-drug interactions related to cytochrome P450 enzyme systems.

Elimination: The primary route of elimination is renal excretion of unchanged drug through glomerular filtration and proximal tubular secretion. The half-life of alendronate in plasma is approximately 1 to 2 hours; however, its skeletal half-life is considerably longer, estimated at years due to bone binding, contributing to prolonged pharmacodynamic effects. Renal clearance is rapid in subjects with normal kidney function, but dosage adjustment is advised in patients with significant renal impairment. The drug is not cleared effectively by hemodialysis.

Dosage Forms

Available Dosage Forms:
- Oral tablet: 5 mg, 10 mg, 35 mg, 40 mg, and 70 mg.
- Oral effervescent tablet: 70 mg (available under the brand Binosto).

Dosages for Adults and Adolescents:
- For treatment or prevention of osteoporosis in postmenopausal women: 10 mg once daily or 70 mg once weekly.
- For treatment of osteoporosis in men: 10 mg once daily.
- For treatment of glucocorticoid-induced osteoporosis: 5 mg once daily for men and premenopausal women, 10 mg once daily for postmenopausal women not receiving estrogen.
- For treatment of Paget's disease of bone in adults: 40 mg once daily for 6 months.

Specific Patient Populations:
- Renal impairment: Alendronate is contraindicated in patients with creatinine clearance below 35 mL/min. Caution is advised, and alternative therapies should be considered for severe renal impairment.
- Elderly: No dosage adjustment required but monitor renal function.
- Pediatric use: Safety and efficacy not established.

Clinical guidelines emphasize the necessity of taking the medication on an empty stomach, with at least 6-8 ounces of plain water, and remaining upright for at least 30 minutes post-dose to minimize esophageal irritation.

Mechanism Of Action

Alendronate is a nitrogen-containing bisphosphonate that exerts its effects primarily by inhibiting osteoclast-mediated bone resorption. It binds selectively to hydroxyapatite binding sites on bony surfaces undergoing active resorption. Once internalized by osteoclasts during bone resorption, alendronate inhibits farnesyl pyrophosphate synthase within the mevalonate pathway, a critical component for the prenylation and function of small GTPase signaling proteins crucial for osteoclast activity and survival.

By interrupting this pathway, alendronate induces osteoclast apoptosis, thereby reducing bone resorptive activity and slowing bone turnover. This preservation and potential increase in bone mineral density contribute to the reduced incidence of fractures in patients with osteoporosis.

Compared with non-nitrogenous bisphosphonates which induce osteoclast apoptosis via formation of cytotoxic ATP analogs, alendronate’s inhibition of the mevalonate pathway represents a more potent and specific mechanism, contributing to its clinical efficacy. Clinical studies demonstrate significant reductions in vertebral, nonvertebral, and hip fractures among postmenopausal women treated with alendronate.

Additionally, alendronate modulates the bone remodeling cycle without impairing osteoblast function, allowing bone formation processes to continue relative to resorption, thus restoring or improving skeletal strength. Emerging evidence suggests potential anti-inflammatory and antitumor properties, though these effects remain under investigation.

Pharmacological Actions

Inhibition of osteoclast-mediated bone resorption
Selective binding to hydroxyapatite in bone tissue
Induction of osteoclast apoptosis through mevalonate pathway inhibition
Reduction in bone turnover leading to increased bone mineral density
Prevention of bone loss associated with postmenopausal osteoporosis
Therapeutic effect in steroid-induced osteoporosis
Treatment of Paget's disease via normalization of bone remodeling
Minimal effect on osteoblast function, preserving bone formation
Lack of systemic metabolic transformation of the drug
Renal excretion of unchanged drug
Prolonged skeletal retention enhancing sustained efficacy
Potential protective effect against fractures, including vertebral and hip
Negligible plasma protein binding facilitating tissue distribution
Absence of drug metabolism reducing drug-drug interaction risk
Ability to reduce hypercalcemia secondary to bone resorption

Therapeutic Or Clinical Uses

Treatment and prevention of osteoporosis in postmenopausal women
Treatment of osteoporosis in men to increase bone mass
Management of glucocorticoid-induced osteoporosis in men and women
Treatment of Paget's disease of bone in adult patients
Prevention of bone fractures in at-risk populations with low bone density
Adjunctive therapy to calcium and vitamin D supplementation for bone health
Reducing risk of vertebral and nonvertebral fractures in osteoporosis patients
Treatment of osteoporosis associated with long-term corticosteroid therapy
Improvement of bone mineral density in individuals with established osteoporosis
Potential off-label use in other metabolic bone diseases where inhibition of bone resorption is desired
Management of osteoporosis in patients intolerant to other treatments
Prevention of fractures in elderly populations with high fracture risk
Adjunctive therapy following hip fracture to reduce recurrence
Supportive treatment in bone-related complications of certain cancers (less common use)
Part of a comprehensive osteoporosis management program including lifestyle measures

Side Or Adverse Effects

Esophageal irritation and esophagitis including pain, ulceration, and rarely strictures
Gastrointestinal symptoms such as heartburn, nausea, abdominal pain, diarrhea, and constipation
Musculoskeletal pain including bone, joint, and muscle pain of varying severity
Hypocalcemia especially in patients with pre-existing low serum calcium
Osteonecrosis of the jaw, particularly in patients with dental surgery, cancer, or concomitant corticosteroid therapy
Atypical femoral fractures reported with prolonged use
Rare allergic reactions including hives, wheezing, facial swelling, and anaphylaxis
Inflammatory eye reactions such as uveitis or conjunctivitis (uncommon)
Transient flu-like symptoms may occur after initial dosing in some patients
Renal toxicity is rare but possible in patients with pre-existing kidney disease
Esophageal erosion or perforation if dosing recommendations are not followed
Hypersensitivity reactions including rash and pruritus
Headache reported as a common but mild adverse effect
Jaw pain, swelling, or numbness that may indicate osteonecrosis
Potential for severe heartburn or new/worsening dysphagia requiring medical evaluation

Precautions

Do not use in patients with hypocalcemia; correct calcium levels prior to initiation
Must be able to sit or stand upright for at least 30 minutes after dosing to avoid esophageal irritation
Evaluate dental health before and during therapy; dental procedures increase risk of osteonecrosis of the jaw
Monitor calcium and vitamin D intake to maintain normocalcemia during treatment
Use cautiously in patients with esophageal motility disorders or Barrett's esophagus
Regular monitoring for femoral pain or thigh discomfort to detect atypical fractures early
Avoid concurrent use with calcium supplements, antacids, or other oral medications within 30 minutes post-dose
Exercise caution in patients with renal impairment; contraindicated if creatinine clearance is less than 35 mL/min
Women of childbearing potential should use effective contraception; discontinue if pregnancy occurs
Ensure adequate hydration to reduce GI adverse effects
Assess risk-benefit ratio for long-term use beyond 3–5 years due to rare but serious adverse renal and bone events
Monitor for symptoms of esophagitis including chest pain, severe heartburn, or dysphagia
Educate patients on adherence to administration guidelines to prevent serious esophageal injury
Consider bone mineral density testing periodically to guide duration of therapy
Be vigilant for allergic or hypersensitivity reactions; discontinue if severe

Warnings

Contraindicated in patients with abnormalities of the esophagus which delay esophageal emptying such as strictures or achalasia
Risk of serious esophageal irritation including esophagitis, esophageal ulcers, and strictures; immediate medical attention if symptoms occur
Patients must remain upright for at least 30 minutes after administration to prevent esophageal injury
Rare occurrences of osteonecrosis of the jaw have been reported, particularly in cancer patients receiving high doses
Long-term use has been associated with atypical subtrochanteric and diaphyseal femoral fractures
Hypocalcemia risk especially in predisposed individuals; ensure adequate calcium and vitamin D levels before and during treatment
Use with caution in patients with renal impairment; contraindicated for severe renal dysfunction
Potential interaction with other drugs altering calcium absorption or gastrointestinal motility
Pregnancy category C: Use only if clearly needed; discontinue immediately if pregnancy occurs
Calcium supplements, antacids, and certain other oral medications interfere with alendronate absorption and should be spaced appropriately
Potential for severe musculoskeletal pain necessitating discontinuation in some patients
Discontinue if signs of an allergic reaction occur and seek emergency care
Avoid use in patients unable to comply with dosing instructions due to risk of serious adverse events
Observe for signs of hypocalcemia such as muscle spasms or cramps
Monitor closely patients undergoing invasive dental procedures

Contraindication

Hypocalcemia or other significant disturbances of serum calcium or mineral metabolism
Known hypersensitivity or allergy to alendronate or any component of the formulation
Esophageal abnormalities that delay esophageal emptying including stricture or achalasia
Inability to remain in an upright position (sitting or standing) for at least 30 minutes after dosing
Severe renal impairment defined as creatinine clearance less than 35 mL/min
Patients with active esophagitis or esophageal ulcers
Pediatric patients due to lack of safety and efficacy data
Pregnant or breastfeeding women except in clearly defined circumstances and under medical supervision
Use with caution in patients with gastroduodenal ulcers
Concurrent use with other bisphosphonates for treatment of osteoporosis is not recommended

Drug Interactions

Calcium supplements and antacids interfere with absorption of alendronate; should be taken at least 30 minutes apart
NSAIDs (e.g., ibuprofen, naproxen, celecoxib) may increase risk of gastrointestinal irritation and ulcers
Aspirin may also increase GI adverse effects when taken concomitantly
Concurrent use with other oral medications is not recommended within 30 minutes post alendronate dose due to impaired absorption
Potential interaction with mineral-containing foods or beverages reducing bioavailability
Possible increased risk of hypocalcemia when used with drugs that lower calcium (e.g., corticosteroids)
No significant cytochrome P450 interactions due to lack of metabolism, minimizing systemic drug-drug interactions
Caution with drugs that affect renal function as both may impact kidney clearance
Concurrent use with other bisphosphonates increases risk of additive adverse effects without proven benefit
Use with caution with phosphate binders that can reduce absorption
Management of dosing schedules is crucial to avoid competitive inhibition of absorption with vitamins or supplements
Monitor for enhanced GI side effects when combined with glucocorticoids
No known direct interaction with anticoagulants but clinical vigilance advised during therapy
Concurrent use with drugs reducing esophageal motility or causing esophageal irritation may potentiate risks
Interaction potential exists with muscle relaxants due to shared adverse effect profiles

Preparations Of The Drug

Fosamax tablets: immediate-release oral tablets available in strengths 5 mg, 10 mg, 35 mg, 40 mg, and 70 mg
Binosto: effervescent oral tablet formulation of alendronate 70 mg designed to dissolve in water prior to ingestion
Fosamax Plus D: combination tablet containing alendronate 70 mg and vitamin D3 (cholecalciferol) in 70 mcg or 140 mcg doses for osteoporosis management
Generic alendronate tablets available in multiple strengths paralleling brand formulations
Alendronate formulations intended for oral administration only with specific administration instructions to maximize absorption and reduce side effects
Packaging includes medication guides emphasizing upright positioning and fasting status during dosing
Dosage forms designed with specific coatings to maximize acid stability and minimize esophageal irritation
Multiple commercial manufacturers offer alendronate with comprehensive labeling and prescribing information
No intravenous formulations of alendronate; alternative bisphosphonates available for parenteral administration if needed
Preparation and administration guidelines stress usage with plain water and avoidance of other beverages
Patient education materials provided with all preparations underscore critical adherence steps
Extended-release or sustained-release formulations are not available; standard immediate-release forms predominate
Storage instructions specify room temperature, avoiding moisture and heat exposure
Effervescent preparation requires full dissolution in plain water prior to ingestion for adequate dosing
Combination products facilitate compliance in patients needing vitamin D supplementation along with bisphosphonate therapy